Transcode Therapeutics, Inc. - 8-K Filing

TransCode Therapeutics reported positive results from its Phase 1a clinical trial of TTX-MC138 in metastatic cancer patients. The trial met safety endpoints with no dose-limiting toxicities and showed durable disease stabilization, supporting advancement to a Phase 2a trial targeting ctDNA-positive colorectal cancer. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR · June 3, 2026, 12:57 UTC

Tickers: $RNAZ

Read the full article at SEC EDGAR

More Regulatory news

Bitwise Avalanche ETF - 8-K Filing SEC EDGAR · November 12, 2026, 15:06 UTC
MiNK Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:05 UTC
Future Vision II Acquisition Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
THUNDER MOUNTAIN GOLD INC - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
MiNK Therapeutics, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:49 UTC
SusGlobal Energy Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:42 UTC
Ideal Power Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:25 UTC
DIGI INTERNATIONAL INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:23 UTC
ZeroStack Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC
Sound Point Meridian Capital, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC